Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).
Alejo Rodriguez-VidaAristotelis BamiasEmilio EstebanMaria Isabel SaezMarta Lopez-BreaDaniel CastellanoCristina CaballeroJose Luis Gonzalez-LarribaEmiliano CalvoSonia MaciaAlain RavaudJoaquim BellmuntPublished in: BJU international (2020)
The study failed to show any benefit of alternating cycles of sunitinib and everolimus in patients with mRCC. The alternating approach using an mTOR inhibitor does not seem to prevent the occurrence of resistance to VEGFR blockade.